| NCT ID | NCT07419425 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Wisconsin, Madison |
| Condition | Smoking Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,550 participants |
| Start Date | 2026-07 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 1,550 participants in total. It began in 2026-07 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline. This study compares the relative effectiveness of three different treatments (Standard, Intensive, and Intensive Incentivized) on long-term smoking cessation (biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day) among Black adults who smoke and want to quit.
Eligibility Criteria
Inclusion Criteria: * self-identify as Black * smoke cigarettes (greater than or equal to 1 cigarette on greater than or equal to 4 days/week) * motivated to quit smoking * willing to discontinue any non-study smoking cessation pharmacotherapy use during study treatment. Exclusion Criteria: * currently taking bupropion for non-smoking cessation reasons
Contact & Investigator
Megan Piper, PhD
PRINCIPAL INVESTIGATOR
UW School of Medicine and Public Health
Frequently Asked Questions
Who can join the NCT07419425 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07419425 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07419425 currently recruiting?
Yes, NCT07419425 is actively recruiting participants. Contact the research team at mep@ctri.wisc.edu for enrollment information.
Where is the NCT07419425 trial being conducted?
This trial is being conducted at Phoenix, United States, Indianapolis, United States, Kansas City, United States, Richmond, United States and 1 additional location.
Who is sponsoring the NCT07419425 clinical trial?
NCT07419425 is sponsored by University of Wisconsin, Madison. The principal investigator is Megan Piper, PhD at UW School of Medicine and Public Health. The trial plans to enroll 1,550 participants.